Greg was placed in an induced coma. The news he got on waking was a shock
While he had been unconscious, his family had been told he was unlikely to survive after multiple organ failure brought on by Type 2 diabetes.
Bird had no idea he even had the disease.
The 60-year-old said he had gone in pain to the chemist, who called an ambulance for him.
He was rushed to Midland Hospital before being transferred to Royal Perth Hospital and placed in the coma.
'The diabetes had been sitting there and building up and building up, and it led to the point where the whole system shut down,' he said.
'They didn't think I was going to make it.'
Bird is one of millions of Australians living with diabetes for whom healthcare costs are, on average, double that of someone without the condition – $9677 per person with diabetes annually compared to $4669.
Those figures have come from new research released by researchers from Deakin, La Trobe and Curtin University, who found the total cost of diabetes to Australia's healthcare system was $14.2 billion in 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
3 minutes ago
- Perth Now
‘Toxic' claim against supplement giant
Australian supplement giant Blackmores is facing potential class-action lawsuit, over claims that excessive levels of vitamin B6 in some of the company's over-the-counter products have led to serious health complications. Dominic Noonan-O'Keeffe began taking Blackmores supplements in May 2023 to support his health, ahead of the birth of his first child. Unaware the magnesium product contained potentially 'toxic' levels of vitamin B6, he claims he soon developed severe symptoms – including fatigue, headaches, muscle spasms, heart palpitations, and loss of sensation, according to Polaris lawyers. Doctors later diagnosed him with neuropathy linked to excessive B6 intake. Despite stopping in early 2024, Mr Noonan-O'Keeffe claims he continues to suffer daily from nerve pain and other symptoms. Polaris Lawyers – who are representing Mr Noonan-O'Keeffe, the lead plaintiff in the potential class-action – allege they later discovered the magnesium product contained about 29 times the recommended daily intake of vitamin B6. Mr Noonan-O'Keeffe claims he suffered lasting health impacts after taking Blackmores Magnesium+. Supplied Credit: Supplied Polaris Lawyers is now investigating a proposed class action against Blackmores for the excessive B6 levels in their vitamin supplements. 'It's alarming to walk down the vitamin aisle of any chemist in Australia and see vitamin supplements containing levels of B6 which are far and above the recommended daily intake,' Polaris Lawyers Founder and Principal Nick Mann said. 'What happened to Dominic is tragic, but he is not alone – we are aware of reports that excessive levels of B6 in over-the-counter supplements may have caused lasting injuries to hundreds of Australians. 'Polaris Lawyers is currently investigating a class action on behalf of anyone who has suffered injuries as a result of excessive levels of B6 as a result of taking Blackmores vitamin supplements.' Blackmores is one of the country's biggest supplement providers. Supplied Credit: Supplied In an interim decision report released in June, the TGA acknowledged no clear consensus on a safe vitamin B6 level that fully prevents peripheral neuropathy. The decision proposed rescheduling products containing over 50mg per day as 'Pharmacist Only Medicines.' A Blackmores spokesperson said they were aware of the TGA's proposed changes. 'At Blackmores, we are committed to the highest standards of product quality and consumer safety. All our products, including those containing Vitamin B6, are developed in strict accordance with the regulatory requirements of the Therapeutic Goods Administration (TGA),' the spokesperson said. 'This includes compliance with maximum permitted daily doses and the inclusion of mandated warning statements. 'We acknowledge the interim decision issued by the TGA and we will ensure full compliance with its final determination.'
7NEWS
5 hours ago
- 7NEWS
Class action looms over Blackmores after vitamin B6 toxicity causes ‘tragic' injuries to expecting father
A young father left with devastating injuries is at the centre of a looming class action against a popular Australian health supplement company. Dominic Noonan-O'Keeffe says he was taking multiple over-the-counter Blackmores supplements, to bolster his health before becoming a father. But one magnesium product he was taking contained 29 times the recommended daily intake of vitamin B6 — making it toxic to his body, according to Polaris Lawyers. WATCH THE VIDEO ABOVE: Class action on the cards for popular health supplement company. The Melbourne law firm's founder and principal Nick Mann said he is aware of hundreds of Australians reporting lasting injuries from B6 consumed through over-the-counter supplements. While B6 is an essential vitamin for the brain, nervous system, immune system, hormonal regulation and metabolism, and can be found naturally in food — too much is toxic. It can leave those who consume unsafe amounts with nerve damage, migraines, heart spasms, and sensations of burning or numbness across the body. For Noonan-O'Keeffe, 'significant fatigue, excruciating headaches and hypersensitivity to his environment' began in August 2023, three months after he began taking Blackmores supplements. 'His symptoms escalated, with Dominic experiencing muscle spasms, neuralgia, heart palpitations, visual disturbances and loss of sensation across his body,' Polaris Lawyers said. 'Dominic was left unable to concentrate, struggling to sleep, constantly in pain and even at times found it difficult walking. His medical team would go on to identify neuropathy caused by excessive B6 levels in the Blackmores supplements.' Such symptoms of B6 toxicity are widely reported, but the Therapeutic Goods Administration (TGA) said that 'many people are not aware' of them, in a 2022 alert to raise awareness. This alert was published by the TGA one month after it strengthened labelling requirements on products with daily doses that included over 10mg of vitamin B6. Noonan-O'Keeffe wants further changes to the way supplements are sold. In a June interim decision report discussing amendment to the Poisons Standard, the TGA could not find a consensus on the levels of B6 safe enough to totally ensure against the development of peripheral neuropathy. 'Previously, it was generally considered that high intake greater than 200mg per day taken over a long period of time was required to develop peripheral neuropathy,' TGA said. But it cited a European literature review which found supplemental doses of less than 50mg per day had caused peripheral neuropathy in some people, and there were notes of 'large inter-individual differences in sensitivity to vitamin B6 toxicity'. The TGA listed 174 reports of nerve-damage conditions as of June 4, and cited concerns of under-reporting. In its 2022 warning, the TGA said that in many cases of adverse reactions to B6 toxicity, patients 'were unaware they had consumed vitamin B6 as the product they were taking was a magnesium supplement'. Of the 32 cases of peripheral neuropathy under review at the time of the alert, 28 per cent involved 'multiple medicines containing vitamin B6, some of which did not have a label warning because they contained less than 50mg of vitamin B6.' In the class action call-out for anyone who believes they may have suffered injuries as a result of B6 toxicity, Polaris Lawyers described how Noonan-O'Keeffe 'could not have imagined the significant long term medical problems that taking the supplement would cause'. Mann said Noonan-O'Keeffe's case was 'tragic' but noted that he 'is not alone'. ''It's alarming to walk down the vitamin aisle of any chemist in Australia and see vitamin supplements containing levels of B6 which are far and above the recommended daily intake.' The TGA interim decision outlines a rescheduling of vitamin B6, so that products with daily dosages over 50mg will be classified as 'Pharmacist Only Medicines'. A Blackmores spokesperson told 'All our products, including those containing Vitamin B6, are developed in strict accordance with the regulatory requirements of the TGA 'This includes compliance with maximum permitted daily doses and the inclusion of mandated warning statements. We acknowledge the interim decision issued by the TGA, and we will ensure full compliance with its final determination.'
AU Financial Review
9 hours ago
- AU Financial Review
Trade stand-off continues as US drug tariffs loom
Australia's pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US threats to triple the price of foreign medicines. In a continuation of his erratic approach to trade policy, President Donald Trump says taxes on drug imports could be announced as soon as the end of the month, with eventual tariff rates of up to 200 per cent. 'We're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff,' Trump said. Australia's Pharmaceutical Benefits Scheme, under which the government negotiates medicine prices with manufacturers before subsidising them for patients, is reportedly in the crosshairs of US pharmaceutical companies lobbying the White House. The Albanese government has flatly refused any negotiation on the PBS. 'Obviously, they are being lobbied, as other US presidents have been for many years by the US big pharma industry, which wants not just Australia's scheme but other schemes like it around the world ... they want that freed up,' federal health minister Mark Butler said on Wednesday. 'They want to see their profits increased. That's been the case for decades and decades.' The PBS is crucial to ensure equitable and affordable access to medicines, according to Royal Australian College of GPs president Michael Wright. 'We should be proud of the prime minister and treasurer's steadfast support for maintaining the PBS, regardless of external pressure.' But complaints about such pricing schemes are common across the industry and include Australian medicine manufacturers, says Melbourne University research fellow Joe Carrello. 'They argue the increasing costs it takes to investigate and run trials and bring a new drug to market aren't keeping up with what the return is, given what the government is willing to pay,' Dr Carrello said. Dr Carrello, who helps evaluate medicines proposed for the PBS after their approval by the Therapeutic Goods Administration, said there could be consequences to a relatively small market like Australia negotiating such lean prices. 'The fear is some US companies may decide against launching new drugs in Australia because comparatively, they're not going to get a good price,' he said. In the US, where a relatively free-market approach has been favoured, drug prices are almost three times higher than in 33 comparable income countries, according to RAND research. Australians have an average life expectancy of 83.2 years, compared to 77.4 years in the US, World Bank data shows. 'Without the PBS, we'd see people losing access to affordable medications and an increased spend per person on average but it wouldn't be evenly distributed,' Dr Carrello said.
